PharmaShots | Incisive News in 3 Shots

Subscribe Now

2.0 mg)

Novo Nordisk Report Submission of label Expansion Application to US FDA's for Ozempic (semaglutide) for T2D

Novo Nordisk Report Submission of label Expansion Application to US FDA's for Ozempic (semaglutide) for T2D

January 21, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us